Frank Yocca insider trades: BioXcel Therapeutics (BTAI) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Frank reports to the SEC
Open-market buys and sales
15 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| May 20, 2026 | BTAI | ↓ Sell | 6,845 | $1.08 | $7K | Direct | May 22, 2026 (2d) |
| Dec 16, 2024 | BTAI | ↓ Sell | 430 | $0.35 | $152 | Direct | Dec 17, 2024 (1d) |
| Oct 3, 2024 | BTAI | ↓ Sell | 7,175 | $0.55 | $4K | Direct | Oct 3, 2024 (0d) |
| Sep 16, 2024 | BTAI | ↓ Sell | 355 | $0.69 | $245 | Direct | Sep 17, 2024 (1d) |
| Jun 17, 2024 | BTAI | ↓ Sell | 372 | $1.28 | $476 | Direct | Jun 18, 2024 (1d) |
| Apr 4, 2024 | BTAI | ↓ Sell | 1,067 | $2.63 | $3K | Direct | Apr 8, 2024 (4d) |
| Mar 15, 2023 | BTAI | ↓ Sell10b5-1 | 985 | $19.69 | $19K | Direct | Mar 16, 2023 (1d) |
| Jan 20, 2023 | BTAI | ↓ Sell | 50,000 | $30.00 | $1.5M | Direct | Jan 24, 2023 (4d) |
| Mar 15, 2021 | BTAI | ↓ Sell | 15,000 | $48.50 | $728K | Direct | Mar 17, 2021 (2d) |
| Feb 16, 2021 | BTAI | ↓ Sell | 15,000 | $57.68 | $865K | Direct | Feb 18, 2021 (2d) |
| Jan 25, 2021 | BTAI | ↓ Sell | 15,000 | $48.39 | $726K | Direct | Jan 27, 2021 (2d) |
| Aug 13, 2019 | BTAI | ↑ Buy | 6,547 | $8.67 | $57K | Direct | Aug 14, 2019 (1d) |
| Dec 4, 2018 | BTAI | ↑ Buy | 900 | $5.21 | $5K | Direct | Dec 6, 2018 (2d) |
| Nov 30, 2018 | BTAI | ↑ Buy | 450 | $5.20 | $2K | Direct | Nov 30, 2018 (0d) |
| Nov 29, 2018 | BTAI | ↑ Buy | 500 | $5.02 | $3K | Direct | Nov 30, 2018 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other BTAI insiders
Open-market trades in the last 12 months
About Frank Yocca's insider trades
Frank Yocca is Chief Scientific Officer at BioXcel Therapeutics (BTAI). Since Nov 29, 2018, Frank has reported 4 open-market purchases worth $66K and 11 sales worth $3.9M on SEC Form 4. In the last 12 months: 1 sale ($7K).
1 sale (1% of the value sold) was made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so it says little about how the insider sees the stock today.
Their filings also include option exercises (18 filings), grants and awards (11 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every BTAI insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.